CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.89 | -1.20 | -0.03 | 0.15 |
| FCF Yield | -2.91% | -15.30% | -28.95% | -11.32% |
| EV / EBITDA | -28.18 | -6.72 | -1.91 | -7.33 |
| Quality | ||||
| ROIC | -24.93% | -82.18% | -48.83% | -34.76% |
| Gross Margin | 97.81% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.79 | 0.77 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 13.36% | -21.16% | -55.36% | 54.45% |
| Safety | ||||
| Net Debt / EBITDA | 1.07 | -0.76 | 0.86 | 0.53 |
| Interest Coverage | -5.37 | -6.25 | -33.91 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,051.72 | -563.44 | -1,447.27 | -133.41 |